NCT05991362View on ClinicalTrials.gov

A Phase I Study of GFH312 in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

February 13, 2023

Study Completion Date

May 30, 2023

Conditions
Healthy Volunteer
Interventions
DRUG

GFH312 100 mg

Participants receive single dose of GFH312 100 mg orally

DRUG

GFH312 200 mg

Participants receive single dose of GFH312 200 mg orally

DRUG

GFH312 120mg

Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days

OTHER

Placebo

Participants receive placebo matching with GFH312

Trial Locations (1)

Unknown

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Zhejiang Genfleet Therapeutics Co., Ltd.

INDUSTRY